Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.51 USD

73.51
8,106,663

+0.21 (0.29%)

Updated Jul 18, 2024 04:00 PM ET

After-Market: $73.37 -0.14 (-0.19%) 6:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Mark Vickery headshot

Positive Data for Gilead's (GILD) Remdesivir; Plus Q1 for BA, GE

This is obviously remarkably good news for COVID-19 suffers, the general public in the throes of this pandemic, and of course Gilead itself.

Biotech Stocks Earnings Roster for Apr 30: AMGN, GILD & More

Let us take a look at what is in store for some of the biotech stocks, which are scheduled to report on Apr 30.

Sheraz Mian headshot

Top Stock Research Reports for Cisco, Abbott, NextEra & Others

Today's Research Daily features new research reports on 16 major stocks, including Cisco (CSCO), Abbott Laboratories (ABT) and NextEra Energy (NEE).

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports first-quarter results.

Sweta Killa headshot

First-Mover Pandemic Disease Fight ETF On The Way

Pacer Financial has filed for Pacer BioThreat ETF to enjoy the first-mover advantage that provide investors an option to capitalize on the new opportunities triggered by coronavirus.

Will Strong HIV Sales Drive Gilead's (GILD) Q1 Earnings?

Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on the experimental coronavirus treatment when Gilead (GILD) reports first-quarter 2020 results.

Should Franklin LibertyQ U.S. Equity ETF (FLQL) Be on Your Investing Radar?

Style Box ETF report for FLQL

Focus on Coronavirus Treatments to Boost Biotech Stocks

With the coronavirus pandemic raging on, biotech companies are in focus as they are racing against time to evaluate every possible therapy to combat the spread.

David Borun headshot

Equities See Modest Declines as Many Businesses Prepare to Reopen

A reduction in Coronavirus cases and public outcry have many states planning a resumption of business activities.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Sanghamitra Saha headshot

Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

Acorda (ACOR) to Report Q1 Earnings: What's in the Cards?

During Acorda's (ACOR) upcoming Q1 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug, Inbrija.

Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.

Will Gilead (GILD) Beat Q1 Earnings Despite Coronavirus Mayhem?

Investors will focus on the HIV franchise's performance along with updates on experimental coronavirus treatment, when Gilead (GILD) reports first-quarter 2020 results.

Stock Market News for Apr 24, 2020

U.S. stocks moved little in Thursday's session, due to lack of any solid market-moving news.

Daniel Laboe headshot

Are The Equity Markets Over Optimistic?

The global economy has been put into a medically induced coma, with the pandemic forcing economies around the world to pause

Sweta Jaiswal, FRM headshot

Ride Out the Coronavirus Mayhem With These ETF Areas

We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs Looks Strong Ahead of Q1 Earnings

The healthcare sector has been on a tear driven by potential vaccines and treatments for COVID-19.

Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Sweta Jaiswal, FRM headshot

Biotech ETFs Gaining on Progress in Coronavirus Treatment

The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.

Sweta Killa headshot

Coronavirus Makes Biotech ETFs Red Hot

The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.

The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit

The Zacks Analyst Blog Highlights: Alphabet, Gilead Sciences, Starbucks, Tesla and Intuit

Sanghamitra Saha headshot

4 Top Sectors of Last Week & Their Winning ETFs

These sectors topped last week and beat the broader market in a sweeping move.